(NASDAQ: VNDA) VANDA PHARMACEUTICALS's forecast annual revenue growth rate of 0.72% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 17.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.29%.
VANDA PHARMACEUTICALS's revenue in 2022 is $266,205,000.On average, 1 Wall Street analysts forecast VNDA's revenue for 2022 to be $14,975,422,651, with the lowest VNDA revenue forecast at $14,975,422,651, and the highest VNDA revenue forecast at $14,975,422,651. On average, 1 Wall Street analysts forecast VNDA's revenue for 2023 to be $15,167,487,672, with the lowest VNDA revenue forecast at $15,167,487,672, and the highest VNDA revenue forecast at $15,167,487,672.
In 2024, VNDA is forecast to generate $15,365,201,664 in revenue, with the lowest revenue forecast at $15,365,201,664 and the highest revenue forecast at $15,365,201,664.